Skip to NavigationSkip to content

Chinese company starts mass producing Gilead coronavirus drug

Published on 12/02/20 at 10:10am

A drugmaker in China said it has started mass producing Gilead Sciences Ebola drug that has the potential to fight the coronavirus.

It will be developed by BrightGene Bio-Medical Technology. They said in a statement, filed to the Shanghai Stock Exchange,it has the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead’s drug that is a leading candidate to treat the coronavirus.

However, they may be an infringing on Gilead’s intellectual property. BrightGene has said it intends to license the drug but this has not been approved. It comes a week after Chinese researchers fired a patent for a drug to treat coronavirus.

The researchers are currently testing remdesivir on 761 patients in clinical trials in Wuhan. If BrightGene does get the license to patent the drug, it will need to conduct more trials and get regulatory approval to sell it.

The drug successfully treated a 35 year old American man with the coronavirus in January, and Gilead has been providing the treatment to Chinese researchers for free. Gilead had previously stockpiled the drug for the Ebola outbreak in 2014, but it failed its clinical trial.

Conor Kavanagh


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches